The increased risk of subsequent primary malignancies (SPM) in survivors of adult-onset Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) remains a challenging clinical problem worldwide. The German cancer registry database, pooled from 14 federal states, was used to calculate the standardized incidence ratio (SIR) and excess absolute risk (EAR) of SPM in 128 587 patients registered with first primary HL/NHL between 1990 and 2012. Conversely, SIRs were also calculated for a subsequent HL/ NHL following other first cancers. The risk of developing SPM was significantly increased over twofold for HL survivors (SIR = 2Á14, EAR = 51Á87 cases/10 000 person-years) and 1Á5-fold for NHL survivors (SIR = 1Á48, EAR = 55Á23) compared with the general German population. For solid cancers, SIRs were significantly elevated (1Á6-and 1Á4-fold; respectively) and were highest (threefold) in patients below 30 years of age upon initial diagnosis. Overall, SIRs were consistently elevated for lip/oral cavity, colon/ rectum, lung, skin melanoma, breast, kidney and thyroid. Significantly increased SIRs for oesophagus, stomach, liver, pancreas, testis, prostate, and brain/central nervous system were observed following NHL only. For certain SPM, SIRs remained significantly elevated more than 10 years following HL/NHL diagnosis. Positive reciprocal associations were demonstrated between HL/NHL and several solid cancers mentioned above; for some, common aetiological mechanisms seem plausible.
The incidence of cancer is significantly increasing worldwide, particularly as a result of an ageing and growing population. Currently, cancer-related deaths account for more than 14% of all deaths worldwide (Ferlay et al, 2015) . In 2012, Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) accounted for 0Á3% and 2Á4% of all cancer-related deaths, respectively (Ferlay et al, 2015) . In the same year, 377 deaths occurred from HL in Germany, in addition to 6362 deaths from NHL (Robert Koch Institute and the Association of population-based Cancer Registries in Germany, 2015) , accounting for 0Á2% and 2Á9% of all cancer deaths, respectively. During the last decades, treatment of both diseases has substantially improved the survival rate of affected patients (Sant et al, 2014) . However, the price for modern treatment options is considerably high, notably with regards to the development of subsequent primary malignancies (SPM), which are now a major cause of morbidity amongst longterm lymphoma survivors and have a large negative impact on survival (Ng et al, 2002; van Eggermond et al, 2014; Matasar et al, 2015) .
Previous population-based studies indicate that adult lymphoma survivors are at an increased risk of developing SPM compared with the general population (Brennan et al, 2005; Dores et al, 2006; Royle et al, 2011; AIRTUM Working Group, 2013; J egu et al, 2014; Lorenzo Bermejo et al, 2014; Morton et al, 2014a; Rossi et al, 2015) . High risks were reported for subsequent haematological and solid malignancies, primarily of the gastrointestinal tract, lung, thyroid, kidney, lip and oral research paper cavity, skin melanoma, female breast, bone and soft tissue. The relative risk of SPM also appears to increase with length of follow-up. Lymphoma treatment, primarily comprising of chemo-and radiotherapy, has been proposed as a cause of this increased risk (Mudie et al, 2006; Swerdlow et al, 2011; Omer et al, 2012; Eichenauer et al, 2014) . However, the elevated risk for some specific cancers types cannot solely be explained by treatment effects. Several potential risk factors related to both first and second malignancies have therefore been proposed, such as immune defects, genetic susceptibility, lifestyle or environmental risk factors (e.g. viral infections, tobacco use or occupational risks), as well as interactions between these factors . A recent analysis also indicates that the proportion of second solid cancers attributed to radiotherapy in adult cancer survivors is relatively small (<10%) suggesting that a larger fraction of SPM could be due to other cancer risk factors (Berrington de Gonzalez et al, 2011) . Additionally, surveillance effects require consideration because lymphoma patients are prone to accidental diagnosis of clinically unapparent cancers, particularly during the initial diagnostic work-up. However, differentiation between all these factors poses a difficultly due to the potential overlapping nature.
Population-based studies provide a useful method of indirectly assessing which of these mechanisms appears to dominate via the analysis of SPM risks over follow-up time and reciprocal risks (bidirectional increased risk between two cancer sites). Common risk factors would be plausible if there is a positive bidirectional association (significantly elevated relative risks of a similar magnitude) between the first and second malignancy, which should be relatively stable over the complete follow-up period, whereas treatment effects appear likely if the association is unidirectional and the risk increases five or more years following initial diagnosis and remains high. Depending on the specific type and course of treatment, the effect might peak between five and 10 years (first-line chemotherapy) or beyond 10 years (radiotherapy or any second-or third-line therapy) (Swerdlow et al, 2011) . Accordingly, many reports on SPM following different types of lympho-haematopoietic malignancies pointed to the reciprocal risk between HL and NHL (Dong & Hemminki, 2001; Dores et al, 2006; Royle et al, 2011) , suggesting common mechanisms, such as immune dysfunctions, alongside treatment effects. However, very little is known about the reciprocal associations between these two types of lymphoma and other cancers (Brennan et al, 2005; Curtis et al, 2006) .
More recently, a national report on SPM in childhood cancer survivors (including lymphoma and leukaemia) has been published by the German Childhood Cancer Registry (Klein et al, 2003; Kaatsch et al, 2009) . Until now, there has been no similar report in survivors of adult-onset lymphoid malignancies in Germany. Therefore, the aim of this study was to provide detailed and up to date estimates of the risk of SPM amongst adult lymphoma survivors, utilising the recently pooled German cancer registry database. Additionally, we evaluated the risk of developing HL and NHL as a subsequent malignancy following other first primary cancers to assess whether reciprocal associations exist.
Materials and Methods

Data source
The database used in the present analysis was obtained from the German Centre for Cancer Registry Data (ZfKD) at the Robert Koch Institute, the German national public health institute. The ZfKD annually collects anonymised cancer incidence and survival data from the cancer registries of all federal states. (Hentschel & Katalinic, 2008) . The pooled data were centrally examined for internal consistency by the ZfKD. It was also verified that multiple primary malignancies were accurately classified and coded by each cancer registry by applying the rules mentioned above. Our analysis was based on data pooled from cancer registries from 14 federal states (Table I) . Data from two newly established registries (Baden-Wuerttemberg and Hesse) were not included, as they did not have data on patients with a follow-up time exceeding 5 years.
C85) at 15 years of age or older during the period from 1990 to 2012, were examined (Table I ). The standardized incidence ratio (SIR) was used as a measure of relative risk for SPM. The SIR (O/E ratio) compares the observed number (O) of SPM in the cohort to the expected number (E). The expected number of subsequent cancer cases was calculated by applying registry-, site-, sex-, age-and calendar periodspecific incidence rates in the general German population to the corresponding person-years at risk in the cohort. The person-years at risk were accumulated for each person from the date of diagnosis of the first primary HL or NHL (1990 NHL ( -2012 until date of death or the end of follow-up (31 December 2012), whichever occurred first (Schoenberg & Myers, 1977) . The observed number of SPM was similarly determined from the date of diagnosis of the first primary HL or NHL to the date of death or end of the study. The 95% confidence intervals (CIs) of the SIRs were computed by assuming a Poisson distribution of the observed cases (Breslow & Day, 1987 Data were pooled from 14 federal states: Schleswig-Holstein (1998 -2012 , Hamburg (1990 -2012 ), Lower Saxony (2003 -2012 , Bremen (1998 Bremen ( -2012 , North Rhine-Westphalia (2006 -2012 , without Muenster, and 1990 -2012 only Muenster), Bavaria (2002 -2012 , RhinelandPalatinate (1998 RhinelandPalatinate ( -2012 , Saarland (1990 -2012 ), Saxony (1995 -2012 ), Berlin (1995 -2012 , Brandenburg (1995 Brandenburg ( -2012 , Mecklenburg-Western Pomerania (1995 -2012 , Saxony-Anhalt (1995 -2012 ), and Thuringia (1995 -2012 . HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma. *After excluding Death Certificate only (DCO) cases, preceding primary malignancies, and patients less than 15 years of age. †For this analysis data were pooled from registries that started before the year 1996. ‡After the diagnosis of the first primary malignant cancer. Table I . Descriptive statistics of patients in the cohort, Germany (1990 Germany ( -2012 In contrast to several other studies, we decided not to exclude 'synchronous' cancers (i.e. those diagnosed within 2 months of the first primary malignancy) from the analysis, mainly as they may also represent cancers that might have shared risk factors that led to their simultaneous development. Cancers diagnosed in the same month were randomly selected as being first or subsequent malignancy i.e. 50% of the observed synchronous cases were set as a first HL/NHL and the remaining 50% of cases were excluded from the analysis. Neither in situ nor benign tumours or non-melanoma skin cancer (C44) incidental cases were considered in the calculations of multiple primaries incidence. Cases reported to the cancer registries via Death Certificate only (DCO) were also excluded from the overall analysis, as these cases usually lack any information regarding the date of diagnosis.
The overall observed number and SIRs of SPM (C00-C97 without C44) following first primary HL and NHL are presented by patients' sex, age at diagnosis (15-29, 30-44, 45-59, 60-74 and ≥75 years of age), years since diagnosis (≤2 months, >2 months to ≤1 year, >1 to ≤5 years, >5 to ≤10 years, and >10 years), and calendar period of diagnosis of first lymphoma. For the analysis of SIR in relation to calendar periods, data from 9 German regions were pooled and selected based on the length of follow-up time (i.e. registries that started before the year 1996). Detailed analyses of the SIRs and EARs by the site of the SPM (24 specific cancer sites sorted according to ICD-10 codes) are also presented. A linear regression analysis was used to estimate P values for trend by follow-up time periods (excluding the period ≤2 months). We additionally evaluated the relative risk of developing HL and NHL as a subsequent malignancy following other primary cancers (solid and haematological) included in the initial analysis. All statistical calculations were conducted by R software (version 3.2.2 [2015] ) (R Core Team, 2015) .
The study was based on the anonymised cancer registry database; therefore informed consent was not required.
Results
A total of 18 423 cases of first primary HL and 110 164 cases of first primary NHL were identified in our database that covers, to a varying extent, the time period from 1990 to 2012 (Table I) . Overall, there were 285 cases of HL and 2084 NHL cases with a simultaneous diagnosis (i.e. in the same month and year) of another cancer, which were randomly assigned as a first or second primary. Only one-quarter of the cases with HL were aged 60 years or older at the time of diagnosis, whereas more than half of the cases with NHL were older than 60 years. Approximately 21% (n = 3838) of HL cases were observed for a period of more than 10 years (overall median follow-up time 5Á1 years, range 0-22 years), whereas this proportion was only 10% (n = 11 314) in the NHL cohort (median 3Á1 years). One thousand and ninetythree (6%) SPM were observed following HL and 7925 (7Á2%) following NHL. Of the observed SPM, approximately 18% (after HL) to 21% (after NHL) occurred within 2 months of the first lymphoma diagnosis and, overall, 28% to 34% occurred during the first year.
Overall subsequent malignancy risks
There was a 2Á1-fold significant increase in the overall risk of developing a SPM at any site (excluding non-melanoma skin cancer) following first primary HL (SIR = 2Á14, 95% CI = 2Á02-2Á27, EAR = 51Á87 per 10 000 person-years) and a 1Á5-fold significant increase following first primary NHL (SIR = 1Á48, 95% CI = 1Á44-1Á51, EAR = 55Á23) compared with the general German population (Table II) . The overall SIR for SPM following first primary HL and NHL was significantly increased in both sexes, and there was no overall gender difference in risk. The SIR was 2-4 times higher among patients diagnosed at ages younger than 30 years compared to those diagnosed at ages 75 years or older.
Following the first HL, the SIR for all SPM was significantly elevated during the whole follow-up period, and was highest within the first 2 months of follow-up (13Á14, 95% CI = 11Á36-15Á13) (Table II) . After the first 2 months, the risk for any subsequent cancer remained relatively stable over the follow-up time with SIR between 1Á68 and 2Á19 (P for trend = 0Á43). Following NHL diagnosis, the overall SIR was highest within the first 2 months (7Á90, 95% CI = 7Á52-8Á29), was slightly elevated between 2 months and 10 years of follow-up with SIR between 1Á21 and 1Á33 and declined to normal levels (1Á03, 95% CI = 0Á94-1Á13) after 10 years of follow-up (P for trend = 0Á13) (Table II) . By calendar years, there were no significant differences in the overall SIR of SPM after HL between the earlier (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) and the most recent time period (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) , while the overall SPM SIR following NHL declined significantly over time (Table II) .
Site-specific subsequent malignancy risks
For site-specific SPM following HL and NHL, SIRs and EARs are shown in Fig 1. The relative risk of developing a subsequent solid malignancy was significantly increased by 59% following HL (SIR = 1Á59, 95% CI = 1Á48-1Á71, EAR = 24Á5) and by 39% following NHL (SIR = 1Á39, 95% CI = 1Á36-1Á42, EAR = 41Á2). Additionally, there was a 8Á8-fold and 2Á5-fold significant increase in the relative risk of all subsequent haematological malignancies following HL and NHL, respectively. After first primary HL, SIRs were significantly elevated for NHL (14-fold), myeloid leukaemia (8Á4-fold), for cancers of the thyroid, lung and kidney and lymphoid leukaemia (ranging between 2-to 5Á2-fold), and moderately increased for skin melanoma, lip/oral cavity, breast and colon/rectum (<2-fold). Following first primary NHL, SIRs were significantly elevated for HL (14-fold), myeloid leukaemia (4Á7-fold), for cancers of the testis, kidney and thyroid (ranging between 2-to 2Á6-fold), and moderately elevated for cancer of the skin melanoma, stomach, lip/oral cavity, lung,
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liver, brain/central nervous system (CNS), oesophagus, colon/rectum, pancreas, breast and prostate (<2-fold). Longterm HL survivors had significantly higher risk of developing lung cancer and leukaemia than NHL survivors ( Fig 1A) . Following both types of lymphoma, lung cancer was observed to be the most frequent subsequent solid cancer and had the highest EAR (10Á2 per 10 000 person-years following HL and 9Á9 per 10 000 person-years following NHL, Fig 1B) .
Site-specific subsequent malignancy risks in relation to age at first diagnosis Overall solid cancer SIR and EAR were further examined in relation to the patients' age upon first diagnosis (Fig 2) . The age-related pattern of risk was roughly similar in both HL and NHL. SIRs were highest (over 3-fold) amongst survivors who were less than 30 years of age when first diagnosed with HL or NHL and decreased significantly with advancing age, especially in HL survivors. The EARs for solid SPM tended to increase with increasing age of patients. In both HL and NHL patients, SIRs for subsequent stomach, colorectal, lung cancers, and NHL, HL, acute lymphoblastic leukaemia (ALL), and acute myeloblastic leukaemia (AML) were highest amongst survivors who were younger than 60 years of age. Subsequent lip/oral cavity, melanoma and breast cancers risks were higher in younger survivors of HL but not NHL. Risks for other SPM appeared to be unrelated to the age of patients at the time of first HL/NHL diagnosis (Tables III and IV) .
Site-specific subsequent malignancy risks in relation to time from diagnosis
Following the first HL (Table V) , the SIR for subsequent lung cancer increased continuously over the follow-up time (P for trend 0Á03), and was found to be 4Á4-fold higher following a period of more than 10 years after initial HL diagnosis. Risks for subsequent breast, colorectal and stomach cancer risks were highest in the first 2 months and more than 10 years following initial HL diagnosis (2Á2-to 3Á6-fold). However, when the ≤2-month follow-up period was excluded, a significant upward trend with increasing followup time was found for only colorectal cancer. The risk for melanoma was highest (up to 2Á3-fold) in the first 5 years following HL diagnosis, while for kidney, thyroid cancers, NHL, myeloma and lymphoid leukaemia, SIRs were highest within the 12 months following HL diagnosis and declined 
Values in bold indicate that the 95% confidence interval did not include the value 1 (statistically significant SIR, P < 0Á05). SPM, subsequent primary malignancies; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma; O, observed number of subsequent primary malignancies; E, expected number of subsequent primary malignancies; SIR, standardized incidence ratio; 95% CI, 95% confidence intervals [lower-upper limits]. *ICD-10 C00-C97 excluding non-melanoma skin cancer (C44). †For this analysis data were pooled from: Hamburg (1990 Hamburg ( -2012 , Muenster (1990 Muenster ( -2012 , Saarland (1990 Saarland ( -2012 , Saxony (1995 Saxony ( -2012 , Berlin (1995 Berlin ( -2012 , Brandenburg (1995 Brandenburg ( -2012 , Mecklenburg-Western Pomerania (1995 -2012 , Saxony-Anhalt (1995 -2012 ), and Thuringia (1995 -2012 .
after that. For subsequent AML, SIR increased to 13Á6-fold at 5-10 years following initial diagnosis and subsequently declined. Following first NHL diagnosis (Table VI) , the SIR for the majority of SPM was highest within the first 12 months and declined to normal levels after 10 years of follow-up, with the exception of melanoma and stomach cancers, and HL and AML, for which SIRs remained significantly elevated more than 10 years after first NHL diagnosis. After excluding the period less than 2 months of follow-up, a significant increasing trend was detected only for cancer of the oesophagus.
Risks of HL and NHL subsequent to other first cancers
Bidirectional increased risks were found between HL and cancers of the colon/rectum, lung, thyroid, melanoma, and other haematological malignancies, such as NHL and chronic lymphoid leukaemia (Table VII) . However, the risk of developing lung cancer following HL was substantially higher (particularly more than 5 years following initial diagnosis) than the reciprocal risk of developing HL after first lung cancer. Bidirectional associations were also found between NHL and several cancer sites except for cancers of the oesophagus, larynx, female genital organs, urinary bladder and brain/CNS (Table VIII) .
Discussion
To date, this is the first registry-based study from Germany documenting the risk of developing SPM following diagnosis of HL and NHL in adults, which should be regarded as a provisional report on the current risks of SPM and form the basis for future comparisons. Our data showed that the risk of SPM at any site was increased over two-fold in HL patients and 1Á5-fold in NHL patients compared with the general German population. In general, our results correspond with previous registry-based studies that have reported SIRs ranging from 1Á6 to 3Á9 following HL (Dong & Hemminki, 2001; Dores et al, 2002 Dores et al, , 2006 Royle et al, 2011; AIR-TUM Working Group, 2013; J egu et al, 2014; Morton et al, 2014a) , and from 1Á12 to 2Á0 following NHL (Dong & Hemminki, 2001; Brennan et al, 2005; Dores et al, 2006; Tward et al, 2006; Royle et al, 2011; AIRTUM Working Group, 2013; J egu et al, 2014; Lorenzo Bermejo et al, 2014; Rossi et al, 2015) . In addition, significantly increased overall SIRs for second solid cancers following HL [SIR = 1Á4 (Dong & Hemminki, 2001 ) to 2Á4 (Dores et al, 2002; Hodgson et al, 2007) ], and NHL [SIR = 1Á11 (Tward et al, 2006) to 1Á65 (Hemminki et al, 2008) ] have also been reported, which are comparable to our estimates (SIR = 1Á59 and 1Á39; respectively). However, the majority of those studies reported increasing overall risks after HL and NHL with follow-up time, whereas our data indicates an increasing risk for HL, but not for NHL.
Reasons for variations of the estimated SIRs among studies are commonly related to differences in the study time periods, number of lymphoma survivors, geographic variations, duration of follow-up and rules applied for the definition and classification of multiple tumours. A large number of clinical-or randomized trial-based studies on second cancer after treatment of HL/NHL have been published worldwide. Although they provide long-term follow-up data, these studies are usually limited by small size and selection bias (e.g. age of patients or treatment groups) which result in Relative (A) and excess absolute risks (B) of any subsequent solid malignancy by age at diagnosis of first lymphoma in Germany, 1990 Germany, -2012 . A The SIR of solid malignancies following first HL and NHL by age at diagnosis. B The EAR of solid malignancies following first HL and NHL by age at diagnosis. SIR, standardized incidence ratio; EAR, excess absolute risk per 10 000 person-years; HL, Hodgkin lymphoma; NHL, non-Hodgkin lymphoma. Solid malignancies (ICD-10 C00-C75), excluding non-melanoma skin cancer (C44) and haematological malignancies (C81-C96). Bold indicates that the 95% confidence interval did not include the value 1 (statistically significant SIR, P < 0Á05).
higher risk estimates (Abrahamsen et al, 2002; Ng et al, 2002; Moser et al, 2006; Sacchi et al, 2008; Swerdlow et al, 2011; Tarella et al, 2011; Omer et al, 2012; van Eggermond et al, 2014) . In addition, most of these studies often calculate person-years at risk starting 1 or 5 years after the initial treatment, thus very limited comparison can be made.
The lower overall SIR for NHL compared to HL appears largely related to the later onset of NHL [median age at diagnosis 70 years for NHL vs. 40 years for HL (Robert Koch Institute and the Association of population-based Cancer Registries in Germany, 2015)]. However, within the same age group, the overall results for HL and NHL were rather similar. Overall, the SIR for solid cancer was significantly higher in younger than older survivors of both types of lymphoma, as demonstrated in several international studies (Brennan et al, 2005; Tward et al, 2006; Hodgson et al, 2007) , suggesting the influence of more intensive treatment (mainly combinations of chemo-and radiotherapy or stem cell transplantation) and/or possibly genetic predisposition in younger patients. The expected steady increase in cancer risk with age in the reference population probably results in higher EAR of solid SPM among patients first diagnosed at older ages (Tward et al, 2006; Hodgson et al, 2007) . This pattern was apparent in our study, which means that the burden of SPM is relatively higher in elderly persons (EAR = 46Á9 for 45-59 years-old HL patients, and EAR = 62Á5 for ≥75 years-old NHL patients).
In addition to the long-term effects of lymphoma treatment, common risk factors, such as immune defects, genetic susceptibilities, lifestyle or environmental risk factors, as well as interactions between these factors have been discussed as potential mechanisms for SPM . Aside from these factors, surveillance effects and misclassification have to be considered as a potential source of increased SIR for lymphoma patients. Surveillance effects can be suspected when the SIR is primarily increased in the first few months following diagnosis, and decreases or normalizes over time. In this case, the SIR should not be interpreted as a relative risk of developing but rather of detecting a SPM shortly after initial HL or NHL. Some cancer sites, such as prostate, thyroid and, to some extent, breast cancer, are known to be potentially clinically unapparent over a long period of time and therefore prone to accidental diagnosis especially during the diagnostic work-up of the first malignancy. Similarly, misclassification would probably be in effect mainly during the first months of follow-up. For instance, misclassification may play a role when HL and NHL or two different types of NHL are diagnosed in the same patient, but also for the typical sites for extra nodal NHL (e.g. stomach) (Brennan et al, 2005) .
By applying the aforementioned principles specified in the introduction, which include the analysis of SIR over time and reciprocal risks, and taking biological plausibility into account, the positive associations described in the results section could be interpreted as follows:
Subsequent malignancies following HL
An excess risk induced by treatment of HL is suggested for lung, colorectal, breast and (potentially) for stomach cancers, as the risk estimates increase over the follow-up time (e.g. lung cancer) or at least are still significantly elevated 10 years after first diagnosis. Previous studies have also linked the risk for these cancers to the long-term effects of radiotherapy, or to the combined radiation and chemotherapy effects Bold indicates that the 95% confidence interval did not include the value 1 (statistically significant SIR, P < 0Á05). SPM, subsequent primary malignancies; O, observed number of subsequent primary malignancies; SIR, standardized incidence ratio; 95% CI, 95% confidence intervals [lower-upper limits]; NHL, non-Hodgkin lymphoma; ICD-10, WHO International Classification of Diseases (10 th revision). *Excluding non-melanoma skin cancer (C44) and haematological malignancies (C81-C96). 
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SPM, subsequent primary malignancies; O, observed number of subsequent primary malignancies; SIR, standardized incidence ratio; 95% CI, 95% confidence intervals [lower-upper limits]; NHL, non-Hodgkin lymphoma; ICD-10, WHO International Classification of Diseases (10 th revision).
*Excluding non-melanoma skin cancer (C44) and haematological malignancies (C81-C96). †For follow-up time periods starting from >2 months. (Abrahamsen et al, 2002; Travis et al, 2002 Travis et al, , 2003 Dores et al, 2006; Bruin et al, 2009; Swerdlow et al, 2011; Omer et al, 2012; Berrington de Gonzalez et al, 2013; Morton et al, 2013; van Eggermond et al, 2014) . For lung cancer, a combination of shared risk factors and treatment effect appears to be present, as the reciprocal risks were significantly elevated but the occurrence of lung cancer after HL was relatively higher than in the opposite direction. Shared risk factors or mechanisms seem to be the most probable explanation for the elevated risk for melanoma. Surveillance effects can be suspected for kidney and thyroid cancer, for the latter probably in combination with shared risk factors. The high SIRs (up to 165Á4) in the first 2 months for subsequent NHL, myeloma and lymphoid leukaemia could reflect misclassifications, while surveillance effects may also add to these excesses. The elevated risk for AML, peaking between 5 and 10 years, suggests a treatment effect, which has been previously linked to the use of alkylating chemotherapy either alone (Swerdlow et al, 2011) or in combination with radiation (Abrahamsen et al, 2002; Omer et al, 2012) . Of note, all subsequent AML cases in the German data were observed for HL patients initially diagnosed in the year 2000 or later (data 
Bold indicates that the 95% confidence interval did not include the value 1 (statistically significant SIR, P < 0Á05). O, observed number of subsequent primary malignancies; SIR, standardized incidence ratio; 95% CI, 95% confidence intervals [lower-upper limits]; HL, Hodgkin lymphoma; ICD-10, WHO International Classification of Diseases (10 th revision).
*Excluding non-melanoma skin cancer (C44) and haematological malignancies (C81-C96). †Excluding non-melanoma skin cancer (C44).
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ª 2017 John Wiley & Sons Ltd not shown), which may be related to the introduction of BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) in the late 1990s for the treatment of advanced-stage HL (Diehl et al, 2003; Eichenauer et al, 2014) .
Subsequent malignancies following NHL
With regard to NHL, shared risk factors appear to generally explain the majority of the positive associations with other SPM, as the respective reciprocal SIRs were elevated to a similar degree (Table VIII) . These findings are highly comparable with findings from a previous international study that used registry data pooled from different countries (Brennan et al, 2005) . Increased risks in the first 2 months after NHL diagnosis for thyroid, melanoma, kidney and some other sites may indicate additional surveillance effects, while for cancer of the stomach, the most affected organ in extranodal onset of NHL (Swerdlow et al, 2008) , misclassification may also play a role. For other haematological malignancies after NHL, results were generally comparable to those following HL. Recent studies (Sacchi et al, 2008; Rossi et al, 2015) have reported increased risks of subsequent AML and solid cancers following indolent NHLs, particularly those treated 
Bold indicates that the 95% confidence interval did not include the value 1 (statistically significant SIR, P < 0Á05). O, observed number of subsequent primary malignancies; SIR, standardized incidence ratio; 95% CI, 95% confidence intervals [lower-upper limits]; NHL, non-Hodgkin lymphoma; ICD-10, WHO International Classification of Diseases (10 th revision).
in the recent time period (after the year 2000). This trend was not observed in our data (data not shown). A clearer conclusion can only be made with follow-up data covering a longer period.
Possible common aetiological factors
Our study confirmed the reciprocal association between both lymphoma subgroups and melanoma consistently found in several epidemiological studies (Adami et al, 1995; Brennan et al, 2005; Hu et al, 2005; Curtis et al, 2006) . The underlying mechanism is not fully understood; generally, the reciprocal risk is thought to be related to a common exposure or mechanism, such as chronic immune suppression. Exposure to ultraviolet radiation (UVR), a known risk factor for melanoma, has also been described as a potential common risk factor for NHL and melanoma (Adami et al, 1995; Hu et al, 2005) . However, there is no conclusive evidence for an association between UVR exposure and the risk of developing NHL/HL, given that results from several recent studies support a protective effect of UVR exposure on NHL (Armstrong & Kricker, 2007) and HL risks (Monnereau et al, 2013) . Tobacco smoking could be a potential shared risk factor between HL, NHL and lung cancer, particularly as there is evidence linking cigarette smoking to HL and NHL risks (Morton et al, 2005; Sergentanis et al, 2013) . In addition, it has been demonstrated that tobacco smoking has a multiplicative effect on treatment-related lung cancer (both radioand chemotherapy) (van Leeuwen et al, 1995; Travis et al, 2002) . In absolute terms, lung cancer was the most frequent subsequent solid cancer following both initial HL and NHL, and the absolute excess for lung cancer risk was considerably higher than for all other solid cancers (around 10 subsequent lung cancer cases per 10 000 patients per year). The positive association between NHL and liver cancer appears biologically plausible, as hepatitis C virus infection could play a role in the aetiology of both NHL and liver cancer (Hjalgrim & Engels, 2008) and might therefore be a potential shared risk factor. On the other hand, alcohol intake, an important risk factor for liver cancer, has been shown to be a protective factor for NHL (Morton et al, 2014b) , which increases the complexity of interpreting results. The biological mechanisms for the possible link between HL/NHL and cancer of the thyroid or kidney remain unclear. Thus, this observation requires additional investigations in future research.
Limitations and strengths of the study
The major limitations of this study include the lack of treatment data. Caution should be exercised in interpreting the overall risk of second haematological malignancies following initial primary HL and NHL (particularly of the lymphoid cell type), but also of some cancer sites typically affected by extranodal onset of lymphoma (e.g. stomach cancer). For these cancers, misclassification of diagnosis appears likely to contribute to the marked increase of SIR particularly in the first 2 months after initial diagnosis. It should be emphasised that even a small amount of misclassification during this period would largely affect the SIR, as the expected number of a specific SPM within the first year tends to be rather small. Incomplete registration of incidental cases may bias the estimated SIR in our data. According to our own estimations based on the mortality/incidence method (Ferlay et al, 2013) , completeness between German registries may vary substantially (Robert Koch Institute and the Association of population-based Cancer Registries in Germany, 2015). However, the overall SIR for solid cancers did not substantially change when data from two registries with the lowest estimated completeness were excluded (SIR = 1Á63 for HL and SIR = 1Á40 for NHL). In addition, underestimation of SPM risk may result from incomplete follow-up data (missed events of death or migration) in some German registries, as this would result in an overestimation of time at risk. In particular for Germany, where most registries were established around the year 2000, the follow-up time is insufficient to fully evaluate the long-term risk of treatmentrelated cancers. A previous SEER-based study including the years 1973-2000 reported that relative risks continue to increase with increasing length of follow-up, reaching threefold and 1Á5-fold more than 20 years following HL and NHL diagnosis, respectively (Dores et al, 2006) . The overall results from Germany primarily rely on patients with a follow-up time of less than 10 years, while a large proportion of included patients were still alive and under risk at the end of the study period. Hence, the SIR by follow-up period may be the more appropriate measure for interpretation and comparison rather than the overall results. Finally, we would like to point out to the explorative character of our analysis. Although we highlighted "statistically significant" results in some of the tables, we did not formally test a predefined hypothesis. Therefore, it seems likely that some of the results that appeared to be statistically significant were due to random variations, as multiple testing was in place.
The strengths of the present study include the large size of the study cohort and the inclusion of all SPM (second or more). The large dataset also enabled us to execute stratified analyses of risk by sex, age, follow-up duration and calendar year of diagnosis, as well as the calculation of bidirectional risk estimates, providing more accurate and detailed descriptions of the current risks of SPM in Germany. In addition, the study used pooled data, which should represent a large part of the German population. The application of standardized rules for coding multiple primary malignancies by the regional cancer registries has enabled the comparability of data, and the additional centralized check of the pooled data for multiple primaries at the German Centre for Cancer Registry Data has guaranteed a high internal validity of the database. The reciprocal risks were also assessed in relation to follow-up time considering that cancers sharing similar risk factors might not be necessarily observed simultaneously 
Conclusions
In summary, the pooled German data confirms previous reports in most aspects regarding the increased risk of SPM in adult lymphoma survivors. Despite the relatively short follow-up time, a treatment effect was suggested for some cancers in this study, which was more pronounced among HL survivors. In addition, the reciprocal risks of HL or NHL with some solid cancers suggest common aetiological factors. An increased detection rate due to intensive medical monitoring of patients is also expected to play a role. The increasing set of cancer registry data in Germany (with nationwide coverage achieved in 2009) and the inclusion of data from clinical registries, that will be built up nationwide until 2017 in accordance with the Cancer Screening and Registration Act (Hofst€ adter & Hentschel, 2014) , will provide more accurate results on long-term risks of multiple primary malignancies in the future. Therefore, and as a consequence of recent modifications of lymphoma treatment strategies, further examination of the risks should be performed.
